iBio, Inc. (IBIO)
| Market Cap | 18.20M |
| Revenue (ttm) | 50,000 |
| Net Income (ttm) | -23.16M |
| Shares Out | 8.62M |
| EPS (ttm) | -4.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,487 |
| Open | 2.060 |
| Previous Close | 1.980 |
| Day's Range | 2.060 - 2.200 |
| 52-Week Range | 1.020 - 19.200 |
| Beta | -3.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2024 |
About IBIO
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers;... [Read more]
Financial Performance
Financial StatementsNews
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial r...
iBio stock nearly tripled on Wednesday: here's why
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –
iBio Announces $15.0 Million Private Placement
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven i...
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
– Deal includes $1 million upfront and potential future milestone payments – – iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, T...
iBio Announces Participation in 23rd Annual PepTalk Conference
- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - - VP of Platform Technologies, Matt Gr...
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
iBio Amends and Extends Maturity of Credit Agreement
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (N...
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000...
iBio Announces Reverse Stock Split
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the ...
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -
iBio Explains Recent Filing of Registration Statement
– No new securities are being registered under the Post-Effective Amendment – – No new securities are being registered under the Post-Effective Amendment –
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the fili...
iBio Announces Amendment to Credit Agreement with Woodforest
– Extends maturity date to December 31, 2023 – – Allows time to close pending sale of CDMO facility – BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or ...
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets –
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth
– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...
iBio Forges Research Collaboration with the National Institutes of Health
– NIH to evaluate iBio's patented AI-driven epitope steering platform for Lassa fever vaccine development –
iBio to Participate in the JMP Securities Life Sciences Conference
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its I...
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given to...
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
– Immuno-oncology candidate discovered using iBio's AI epitope steering platform –
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
- Company has directed antibodies against a specific region of MUC16 -
iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its pre...
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its pre...
iBio Announces Proposed Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer an...
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two pos...